Undertakings

• Summary
• Publication of VCUs (PDF)

---

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

---

A

ADENOSCAN

• Voluntary Compliance Undertakings (VCU)
  • VCU – May 2010 (PDF)

AIROMIR (May 2007)

• VCU by 3M Canada Company(PDF)
• Board Order(PDF)
• Press Release(PDF)

ANAPROX (August 1999)

• VCU by Hoffmann-La Roche Limited (PDF)

ANDRIOL (September 2009)

• VCU by Schering-Plough Canada Inc. (PDF)

ANDROGEL (June 2008)

• VCU by Solvay Phama Inc. (PDF)

AROMASIN (April 2003)

• VCU by Pharmacia Canada Inc.

Top of page

---

B

BREVIBLOC

• VCU (PDF)

BUSULFEX

• VCU by ESP Pharma (November 2004)
• VCU by Otsuka America Pharmaceutical, Inc. (June 2010)

Top of page

---

C

CERETEC (July 2005)

• VCU by Amersham Health Inc. (PDF)

CLARITIN

• VCU (PDF)

CONCERTA (April 2009)

• VCU by Janssen-Ortho Inc. (PDF)
• Board Order (PDF)
• Communiqué (PDF)

Top of page

---

D

DENAVIR (April 2008)

• VCU by Barrier Therapeutics Canada Inc. (PDF)

DIFFERIN PLEDGET (September 2002)

• VCU by Galderma Canada Inc. (PDF)

DOSTINEX (October 2003)

• VCU by Pfizer Canada Inc.
• VCU – October 2003 Newsletter Excerpt

DOVOBET (December 2007)

• VCU By LEO Pharma Inc. (PDF)

DUKORAL (December 2005)

• VCU by Sanofi Pasteur Limited (PDF) 
  Accepted by the Vice Chairperson, December 15, 2005

Top of page

---

E

Eligard (April 2009)

• VCU by sanofi-aventis Canada Inc. (PDF) approved by the Chairman of the Board on April 20, 2009

ELOXATIN (July 2006)

• VCU by sanofi-aventis Canada Inc. (Sanofi-Aventis) (PDF) VCU accepted by the Chairperson on July 14, 2006

EVRA (February 2005)

• Voluntary Compliance Undertaking UPDATE, March 1, 2005 / Levaquin
• Press Release
• Board Order
• Voluntary Complilance Undertaking
• Joint Submission

Top of page

---

F

FASTURTEC (June 2004)

• Press Release
• Board Order
• Voluntary Compliance Undertaking
• Submission of Board Staff
• Submission of SANOFI-SYTHÉLABO CANADA INC.

FSME-IMMUN (March 2010)

• VCU by Baxter Corporation (PDF)

FORTEO (June 2007)

• VCU by Eli Lilly Canada Inc. (Lilly Canada)(PDF)

Top of page

---

H

HABITROL

• PMPRB-94-D1/HABITROL (PDF)
• PMPRB-94-D2/HABITROL (PDF)
• Voluntary Compliance Undertaking (October 1994) (PDF)

HEXTEND (July 2006)

• VCU by Hospira Healthcare Corporation(PDF) VCU accepted by the Chairperson on July 14, 2006

HUMALOG (April 1998)

• VCU by Eli Lilly (PDF)
• Board Reasons (PDF)

Top of page

---

N

NEULASTA (October 2009)

• VCU by Amgen Canada Inc.(PDF)
• Board Order (PDF)
• Communiqué (PDF)

NUVARING™ (June 2006)

• VCU by Organon Canada Ltd.(PDF)
  VCU accepted by the Vice-Chairperson on June 20, 2006

Top of page

---

L

LANTUS

• VCU (PDF)

LEVEMIR

• Voluntary Compliance Undertakings (VCU)
  • VCU – May 2010 (PDF)

Top of page

---

O

ONE-ALPHA (May 2004)

• VCU by LEO Pharma Inc.

ORTHO 7/7/7 (September 2005)

• VCU by Janssen-Ortho Inc.

OCTREOSCAN (September 2007)

• VCU by Bristol-Myers Squibb Canada Co. (PDF)

Top of page

---

P

PAXIL CR (March 2010)

• VCU by GlaxoSmithKline Inc. (PDF)

PAXIL CR (March 2005)

• VCU by GlaxoSmithKline Inc.(PDF)

PLAVIX (June 2000)

• Notice and Comment, May 13, 2000 (PDF)
• VCU by Bristol-Myers Squibb and Sanofi (PDF)

PROLASTIN (July 2004)

• VCU by Bayer Inc.

Top of page

---

R

REMICADE ( March 31, 2003)

• Press Release
• Board Order
• Voluntary Compliance Undertaking
• Joint Submission 
• D1 - Application for Leave to Intervene - February 17, 2003(PDF)

RISPERDAL (December 2005)

• VCU by  Janssen-Ortho Inc.(PDF) Accepted by the Vice Chairperson, December 15, 2005

RISPERDAL CONSTA (June 2007)

• VCU by Janssen-Ortho Inc.(PDF) 
• Board Order(PDF) 
• Press Release(PDF)

Top of page

---

S

STARLIX (July 2005)

• VCU by Novartis Pharma

STARNOC (July 2004)

• VCU by Servier Canada Inc.

STRATTERA (February 2009)

• VCU by Eli Lilly Canada Inc. (PDF)
• Board Order (PDF)
• Communiqué (PDF)

SUPRAX (March 2009)

• VCU by sanofi-aventis Canada Inc. (PDF) approved by the Chairman of the Board on March 4, 2009

Top of page

---

T

TAMIFLU (March 2005)

• VCU by Hoffmann-La Roche Limited (PDF)

TRINIPATCH

• VCU by NOVARTIS PHARMACEUTICALS CANADA INC. (PDF)

Top of page

---

V

VANIQA

• VCU (PDF)

VEPESID (February 2009)

• VCU by Bristol-Myers Squibb Canada Co. (PDF)

VOLUVEN

• VCU (PDF)

Top of page

---

X

XARELTO

• VCU (PDF) (January 2010) 

Top of page

---

 

Z

ZANAFLEX (October 2001)

• VCU by Draxis Health Inc. (PDF)

ZEMPLAR (September 2007)

• Board Order (PDF)
• VCU (PDF)
• Communiqué (PDF) 

Top of page